Wasan K M, Cassidy S M
Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada.
J Pharm Sci. 1998 Apr;87(4):411-24. doi: 10.1021/js970407a.
The plasma lipoprotein distribution of potential drug candidates is not commonly studied. For some hydrophobic drug candidates, attainment of similar plasma free drug levels has not been associated with uniform production of pharmacological activity in different animal species. It is well-known that plasma lipoprotein lipid profiles vary considerably between different animal species. In addition, human disease states can significantly influence plasma lipoprotein profiles, resulting in altered therapeutic outcomes. Current research has shown that lipoprotein binding of drug compounds can significantly influence not only the pharmacological and pharmacokinetic properties of the drug, but the relative toxicity as well. Elucidation of drug distribution among plasma lipoproteins is expected to yield valuable insight into factors governing the pharmacological activity and potential toxicity of the drug. This paper will present an historical perspective and summarize the latest research in the area of lipoprotein-drug interactions.
潜在药物候选物的血浆脂蛋白分布通常未被研究。对于一些疏水性药物候选物,在不同动物物种中达到相似的血浆游离药物水平与药理活性的均匀产生并无关联。众所周知,不同动物物种之间的血浆脂蛋白脂质谱差异很大。此外,人类疾病状态可显著影响血浆脂蛋白谱,从而导致治疗结果改变。目前的研究表明,药物化合物与脂蛋白的结合不仅可显著影响药物的药理和药代动力学性质,还可影响相对毒性。阐明药物在血浆脂蛋白中的分布有望为控制药物药理活性和潜在毒性的因素提供有价值的见解。本文将呈现一个历史视角并总结脂蛋白 - 药物相互作用领域的最新研究。